- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Chronic Myeloid Leukemia (CML) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Chronic Myeloid Leukemia (CML) Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Chronic Myeloid Leukemia (CML) Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Targeted Therapy segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Chronic Myeloid Leukemia (CML) Treatment include Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., and Pfizer, Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chronic Myeloid Leukemia (CML) Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Targeted Therapy
Chemotherapy
Radiation Therapy
Splenectomy
Stem Cell Transplant
Market segment by Application, can be divided into
Hospitals
Clinic
Others
Market segment by players, this report covers
Novartis AG
Bristol-Myers Squibb
Teva Pharmaceuticals Industries Ltd.
ARIAD Pharmaceuticals, Inc.
Pfizer, Inc.
Hospira, Inc.
Prism Pharmaceuticals
Incyte Corporation
Bio-Path Holdings
Stragen Pharma SA
Otsuka Pharmaceutical Co., Ltd.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Chronic Myeloid Leukemia (CML) Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Chronic Myeloid Leukemia (CML) Treatment, with revenue, gross margin and global market share of Chronic Myeloid Leukemia (CML) Treatment from 2019 to 2022.
Chapter 3, the Chronic Myeloid Leukemia (CML) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Chronic Myeloid Leukemia (CML) Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Chronic Myeloid Leukemia (CML) Treatment research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Chronic Myeloid Leukemia (CML) Treatment
1.2 Classification of Chronic Myeloid Leukemia (CML) Treatment by Type
1.2.1 Overview: Global Chronic Myeloid Leukemia (CML) Treatment Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Type in 2021
1.2.3 Targeted Therapy
1.2.4 Chemotherapy
1.2.5 Radiation Therapy
1.2.6 Splenectomy
1.2.7 Stem Cell Transplant
1.3 Global Chronic Myeloid Leukemia (CML) Treatment Market by Application
1.3.1 Overview: Global Chronic Myeloid Leukemia (CML) Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Global Chronic Myeloid Leukemia (CML) Treatment Market Size & Forecast
1.5 Global Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast by Region
1.5.1 Global Chronic Myeloid Leukemia (CML) Treatment Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Chronic Myeloid Leukemia (CML) Treatment Market Size by Region, (2017-2022)
1.5.3 North America Chronic Myeloid Leukemia (CML) Treatment Market Size and Prospect (2017-2028)
1.5.4 Europe Chronic Myeloid Leukemia (CML) Treatment Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Size and Prospect (2017-2028)
1.5.6 South America Chronic Myeloid Leukemia (CML) Treatment Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Chronic Myeloid Leukemia (CML) Treatment Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Chronic Myeloid Leukemia (CML) Treatment Market Drivers
1.6.2 Chronic Myeloid Leukemia (CML) Treatment Market Restraints
1.6.3 Chronic Myeloid Leukemia (CML) Treatment Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 Novartis AG
2.1.1 Novartis AG Details
2.1.2 Novartis AG Major Business
2.1.3 Novartis AG Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.1.4 Novartis AG Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Novartis AG Recent Developments and Future Plans
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.2.4 Bristol-Myers Squibb Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.3 Teva Pharmaceuticals Industries Ltd.
2.3.1 Teva Pharmaceuticals Industries Ltd. Details
2.3.2 Teva Pharmaceuticals Industries Ltd. Major Business
2.3.3 Teva Pharmaceuticals Industries Ltd. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.3.4 Teva Pharmaceuticals Industries Ltd. Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Teva Pharmaceuticals Industries Ltd. Recent Developments and Future Plans
2.4 ARIAD Pharmaceuticals, Inc.
2.4.1 ARIAD Pharmaceuticals, Inc. Details
2.4.2 ARIAD Pharmaceuticals, Inc. Major Business
2.4.3 ARIAD Pharmaceuticals, Inc. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.4.4 ARIAD Pharmaceuticals, Inc. Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 ARIAD Pharmaceuticals, Inc. Recent Developments and Future Plans
2.5 Pfizer, Inc.
2.5.1 Pfizer, Inc. Details
2.5.2 Pfizer, Inc. Major Business
2.5.3 Pfizer, Inc. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.5.4 Pfizer, Inc. Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Pfizer, Inc. Recent Developments and Future Plans
2.6 Hospira, Inc.
2.6.1 Hospira, Inc. Details
2.6.2 Hospira, Inc. Major Business
2.6.3 Hospira, Inc. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.6.4 Hospira, Inc. Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Hospira, Inc. Recent Developments and Future Plans
2.7 Prism Pharmaceuticals
2.7.1 Prism Pharmaceuticals Details
2.7.2 Prism Pharmaceuticals Major Business
2.7.3 Prism Pharmaceuticals Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.7.4 Prism Pharmaceuticals Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Prism Pharmaceuticals Recent Developments and Future Plans
2.8 Incyte Corporation
2.8.1 Incyte Corporation Details
2.8.2 Incyte Corporation Major Business
2.8.3 Incyte Corporation Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.8.4 Incyte Corporation Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Incyte Corporation Recent Developments and Future Plans
2.9 Bio-Path Holdings
2.9.1 Bio-Path Holdings Details
2.9.2 Bio-Path Holdings Major Business
2.9.3 Bio-Path Holdings Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.9.4 Bio-Path Holdings Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Bio-Path Holdings Recent Developments and Future Plans
2.10 Stragen Pharma SA
2.10.1 Stragen Pharma SA Details
2.10.2 Stragen Pharma SA Major Business
2.10.3 Stragen Pharma SA Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.10.4 Stragen Pharma SA Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Stragen Pharma SA Recent Developments and Future Plans
2.11 Otsuka Pharmaceutical Co., Ltd.
2.11.1 Otsuka Pharmaceutical Co., Ltd. Details
2.11.2 Otsuka Pharmaceutical Co., Ltd. Major Business
2.11.3 Otsuka Pharmaceutical Co., Ltd. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
2.11.4 Otsuka Pharmaceutical Co., Ltd. Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Chronic Myeloid Leukemia (CML) Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Chronic Myeloid Leukemia (CML) Treatment Players Market Share in 2021
3.2.2 Top 10 Chronic Myeloid Leukemia (CML) Treatment Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Chronic Myeloid Leukemia (CML) Treatment Players Head Office, Products and Services Provided
3.4 Chronic Myeloid Leukemia (CML) Treatment Mergers & Acquisitions
3.5 Chronic Myeloid Leukemia (CML) Treatment New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Chronic Myeloid Leukemia (CML) Treatment Revenue and Market Share by Type (2017-2022)
4.2 Global Chronic Myeloid Leukemia (CML) Treatment Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Application (2017-2022)
5.2 Global Chronic Myeloid Leukemia (CML) Treatment Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2017-2028)
6.2 North America Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2028)
6.3 North America Chronic Myeloid Leukemia (CML) Treatment Market Size by Country
6.3.1 North America Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2017-2028)
6.3.2 United States Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
6.3.3 Canada Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
6.3.4 Mexico Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2017-2028)
7.2 Europe Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2028)
7.3 Europe Chronic Myeloid Leukemia (CML) Treatment Market Size by Country
7.3.1 Europe Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2017-2028)
7.3.2 Germany Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
7.3.3 France Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
7.3.5 Russia Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
7.3.6 Italy Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2017-2028)
8.2 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2028)
8.3 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Size by Region
8.3.1 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue by Region (2017-2028)
8.3.2 China Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
8.3.3 Japan Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
8.3.4 South Korea Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
8.3.5 India Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
8.3.7 Australia Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2017-2028)
9.2 South America Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2028)
9.3 South America Chronic Myeloid Leukemia (CML) Treatment Market Size by Country
9.3.1 South America Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2017-2028)
9.3.2 Brazil Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
9.3.3 Argentina Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2017-2028)
10.2 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2028)
10.3 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Market Size by Country
10.3.1 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2017-2028)
10.3.2 Turkey Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
10.3.4 UAE Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Chronic Myeloid Leukemia (CML) Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Chronic Myeloid Leukemia (CML) Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Chronic Myeloid Leukemia (CML) Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million) by Region (2017-2022)
Table 5. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Region (2023-2028)
Table 6. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 7. Novartis AG Major Business
Table 8. Novartis AG Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 9. Novartis AG Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Major Business
Table 12. Bristol-Myers Squibb Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 13. Bristol-Myers Squibb Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Teva Pharmaceuticals Industries Ltd. Corporate Information, Head Office, and Major Competitors
Table 15. Teva Pharmaceuticals Industries Ltd. Major Business
Table 16. Teva Pharmaceuticals Industries Ltd. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 17. Teva Pharmaceuticals Industries Ltd. Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. ARIAD Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 19. ARIAD Pharmaceuticals, Inc. Major Business
Table 20. ARIAD Pharmaceuticals, Inc. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 21. ARIAD Pharmaceuticals, Inc. Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Pfizer, Inc. Corporate Information, Head Office, and Major Competitors
Table 23. Pfizer, Inc. Major Business
Table 24. Pfizer, Inc. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 25. Pfizer, Inc. Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Hospira, Inc. Corporate Information, Head Office, and Major Competitors
Table 27. Hospira, Inc. Major Business
Table 28. Hospira, Inc. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 29. Hospira, Inc. Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Prism Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Prism Pharmaceuticals Major Business
Table 32. Prism Pharmaceuticals Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 33. Prism Pharmaceuticals Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Incyte Corporation Corporate Information, Head Office, and Major Competitors
Table 35. Incyte Corporation Major Business
Table 36. Incyte Corporation Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 37. Incyte Corporation Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Bio-Path Holdings Corporate Information, Head Office, and Major Competitors
Table 39. Bio-Path Holdings Major Business
Table 40. Bio-Path Holdings Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 41. Bio-Path Holdings Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Stragen Pharma SA Corporate Information, Head Office, and Major Competitors
Table 43. Stragen Pharma SA Major Business
Table 44. Stragen Pharma SA Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 45. Stragen Pharma SA Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Otsuka Pharmaceutical Co., Ltd. Corporate Information, Head Office, and Major Competitors
Table 47. Otsuka Pharmaceutical Co., Ltd. Major Business
Table 48. Otsuka Pharmaceutical Co., Ltd. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
Table 49. Otsuka Pharmaceutical Co., Ltd. Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Global Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 51. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 52. Breakdown of Chronic Myeloid Leukemia (CML) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 53. Chronic Myeloid Leukemia (CML) Treatment Players Head Office, Products and Services Provided
Table 54. Chronic Myeloid Leukemia (CML) Treatment Mergers & Acquisitions in the Past Five Years
Table 55. Chronic Myeloid Leukemia (CML) Treatment New Entrants and Expansion Plans
Table 56. Global Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million) by Type (2017-2022)
Table 57. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Share by Type (2017-2022)
Table 58. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Forecast by Type (2023-2028)
Table 59. Global Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2022)
Table 60. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Forecast by Application (2023-2028)
Table 61. North America Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 62. North America Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 63. North America Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 64. North America Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 65. North America Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 66. North America Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 67. Europe Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 68. Europe Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 69. Europe Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 70. Europe Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 71. Europe Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 72. Europe Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 73. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 74. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 75. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 76. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 77. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue by Region (2017-2022) & (USD Million)
Table 78. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue by Region (2023-2028) & (USD Million)
Table 79. South America Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 80. South America Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 81. South America Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 82. South America Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 83. South America Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 84. South America Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 85. Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 86. Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 87. Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 88. Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 89. Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 90. Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Chronic Myeloid Leukemia (CML) Treatment Picture
Figure 2. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Type in 2021
Figure 3. Targeted Therapy
Figure 4. Chemotherapy
Figure 5. Radiation Therapy
Figure 6. Splenectomy
Figure 7. Stem Cell Transplant
Figure 8. Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Application in 2021
Figure 9. Hospitals Picture
Figure 10. Clinic Picture
Figure 11. Others Picture
Figure 12. Global Chronic Myeloid Leukemia (CML) Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Chronic Myeloid Leukemia (CML) Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Region (2017-2028)
Figure 15. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Region in 2021
Figure 16. North America Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Chronic Myeloid Leukemia (CML) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Chronic Myeloid Leukemia (CML) Treatment Market Drivers
Figure 22. Chronic Myeloid Leukemia (CML) Treatment Market Restraints
Figure 23. Chronic Myeloid Leukemia (CML) Treatment Market Trends
Figure 24. Novartis AG Recent Developments and Future Plans
Figure 25. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 26. Teva Pharmaceuticals Industries Ltd. Recent Developments and Future Plans
Figure 27. ARIAD Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 28. Pfizer, Inc. Recent Developments and Future Plans
Figure 29. Hospira, Inc. Recent Developments and Future Plans
Figure 30. Prism Pharmaceuticals Recent Developments and Future Plans
Figure 31. Incyte Corporation Recent Developments and Future Plans
Figure 32. Bio-Path Holdings Recent Developments and Future Plans
Figure 33. Stragen Pharma SA Recent Developments and Future Plans
Figure 34. Otsuka Pharmaceutical Co., Ltd. Recent Developments and Future Plans
Figure 35. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Share by Players in 2021
Figure 36. Chronic Myeloid Leukemia (CML) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 37. Global Top 3 Players Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share in 2021
Figure 38. Global Top 10 Players Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share in 2021
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 40. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Share by Type in 2021
Figure 41. Global Chronic Myeloid Leukemia (CML) Treatment Market Share Forecast by Type (2023-2028)
Figure 42. Global Chronic Myeloid Leukemia (CML) Treatment Revenue Share by Application in 2021
Figure 43. Global Chronic Myeloid Leukemia (CML) Treatment Market Share Forecast by Application (2023-2028)
Figure 44. North America Chronic Myeloid Leukemia (CML) Treatment Sales Market Share by Type (2017-2028)
Figure 45. North America Chronic Myeloid Leukemia (CML) Treatment Sales Market Share by Application (2017-2028)
Figure 46. North America Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Country (2017-2028)
Figure 47. United States Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Canada Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Mexico Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Europe Chronic Myeloid Leukemia (CML) Treatment Sales Market Share by Type (2017-2028)
Figure 51. Europe Chronic Myeloid Leukemia (CML) Treatment Sales Market Share by Application (2017-2028)
Figure 52. Europe Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Country (2017-2028)
Figure 53. Germany Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. France Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. United Kingdom Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Russia Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Italy Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Sales Market Share by Type (2017-2028)
Figure 59. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Sales Market Share by Application (2017-2028)
Figure 60. Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Region (2017-2028)
Figure 61. China Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Japan Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South Korea Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. India Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Southeast Asia Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Australia Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South America Chronic Myeloid Leukemia (CML) Treatment Sales Market Share by Type (2017-2028)
Figure 68. South America Chronic Myeloid Leukemia (CML) Treatment Sales Market Share by Application (2017-2028)
Figure 69. South America Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East and Africa Chronic Myeloid Leukemia (CML) Treatment Sales Market Share by Type (2017-2028)
Figure 73. Middle East and Africa Chronic Myeloid Leukemia (CML) Treatment Sales Market Share by Application (2017-2028)
Figure 74. Middle East and Africa Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Country (2017-2028)
Figure 75. Turkey Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. UAE Chronic Myeloid Leukemia (CML) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
